Abeona Therapeutics (NASDAQ:ABEO) Releases Quarterly Earnings Results, Beats Expectations By $0.03 EPS

Abeona Therapeutics (NASDAQ:ABEO) issued its quarterly earnings results on Wednesday. The biopharmaceutical company reported ($0.30) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.03, FiscalAI reports. The company had revenue of $8.72 million during the quarter, compared to analyst estimates of $4.57 million.

Here are the key takeaways from Abeona Therapeutics’ conference call:

• ZEVASKYN launch momentum is building, with Abeona treating 5 commercial patients to date, activating 6 qualified treatment centers, and reporting $8.7 million in Q1 2026 net product revenue.
• Management said payer coverage is broadening, with published policies now covering 95% of commercially insured lives and no final payer denials or patient attrition reported so far.
• The company highlighted a deepening patient pipeline, including more than 100 identified patients across centers and the community, plus 45 active referral physicians and several biopsies scheduled this quarter.
• Abeona announced an in-licensed PSMA CAR-T asset for advanced prostate cancer, paid a $7 million upfront fee, and expects first-in-human studies to begin in the second half of 2027 after a June 2026 pre-IND meeting.
• Management said the balance sheet remains strong with $168.3 million in cash and short-term investments, and reiterated expectations for near-term profitability depending on biopsy and treatment cadence.

Abeona Therapeutics Stock Up 0.5%

ABEO stock traded up $0.03 during mid-day trading on Wednesday, reaching $5.71. The company had a trading volume of 2,499,155 shares, compared to its average volume of 1,210,283. The company has a market capitalization of $324.78 million, a price-to-earnings ratio of 5.54 and a beta of 1.35. Abeona Therapeutics has a 52 week low of $4.00 and a 52 week high of $7.54. The stock has a 50 day simple moving average of $5.05 and a two-hundred day simple moving average of $5.04. The company has a debt-to-equity ratio of 0.05, a current ratio of 6.93 and a quick ratio of 6.74.

Analyst Upgrades and Downgrades

ABEO has been the subject of a number of analyst reports. Oppenheimer restated an “outperform” rating on shares of Abeona Therapeutics in a report on Monday, March 9th. Weiss Ratings restated a “sell (d+)” rating on shares of Abeona Therapeutics in a research report on Wednesday, January 21st. HC Wainwright reaffirmed a “buy” rating and set a $20.00 price objective on shares of Abeona Therapeutics in a research note on Thursday, March 19th. Finally, Stifel Nicolaus set a $17.00 target price on Abeona Therapeutics in a report on Tuesday, March 17th. Four research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Abeona Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $19.00.

Insider Activity at Abeona Therapeutics

In other Abeona Therapeutics news, insider Madhav Vasanthavada sold 5,548 shares of Abeona Therapeutics stock in a transaction on Monday, May 11th. The shares were sold at an average price of $5.96, for a total transaction of $33,066.08. Following the completion of the transaction, the insider directly owned 313,071 shares of the company’s stock, valued at $1,865,903.16. The trade was a 1.74% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders own 5.40% of the company’s stock.

Institutional Trading of Abeona Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of ABEO. Legal & General Group Plc bought a new position in Abeona Therapeutics in the second quarter valued at about $27,000. Russell Investments Group Ltd. acquired a new position in Abeona Therapeutics in the 3rd quarter worth about $37,000. Truvestments Capital LLC increased its holdings in Abeona Therapeutics by 191.4% in the 4th quarter. Truvestments Capital LLC now owns 10,307 shares of the biopharmaceutical company’s stock worth $54,000 after purchasing an additional 6,770 shares in the last quarter. Sherbrooke Park Advisers LLC bought a new position in Abeona Therapeutics in the third quarter valued at about $64,000. Finally, Man Group plc acquired a new stake in shares of Abeona Therapeutics during the second quarter valued at about $67,000. Institutional investors own 80.56% of the company’s stock.

Abeona Therapeutics Company Profile

Abeona Therapeutics is a clinical?stage biopharmaceutical company focused on the development and commercialization of gene and cell therapies for severe, life?threatening rare diseases and oncology indications. Founded in 2014 and headquartered in Cleveland, Ohio, Abeona leverages proprietary viral and non?viral delivery platforms to correct or compensate for underlying genetic deficiencies. The company’s research efforts target pediatric neurodegenerative disorders as well as debilitating dermatologic conditions with high unmet medical need.

The company’s lead clinical programs include separate AAV?based gene therapies for CLN1 and CLN3 forms of neuronal ceroid lipofuscinosis, alongside an ex vivo autologous cell therapy for recessive dystrophic epidermolysis bullosa.